Liver Failure - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Liver Failure - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Liver Failure - Pipeline Review, H2 2014', provides an overview of the Liver Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Failure Overview 7
Therapeutics Development 8
Pipeline Products for Liver Failure - Overview 8
Pipeline Products for Liver Failure - Comparative Analysis 9
Liver Failure - Therapeutics under Development by Companies 10
Liver Failure - Therapeutics under Investigation by Universities/Institutes 11
Liver Failure - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Liver Failure - Products under Development by Companies 15
Liver Failure - Products under Investigation by Universities/Institutes 16
Liver Failure - Companies Involved in Therapeutics Development 17
Grifols, S.A. 17
Digna Biotech, S.L. 18
Ventria Bioscience 19
Conatus Pharmaceuticals Inc. 20
Pharmicell Co., Ltd. 21
Alfact Innovation 22
Immune Pharmaceuticals, Inc. 23
Liver Failure - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
emricasan - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ALF-5755 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Livercellgram - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Stem Cell Therapy for Immunology and Gastrointestinal Disorders - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
cardiotrophin-1 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EP-1013 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
talactoferrin alfa - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Stem Cell Therapy for Liver Failure - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TAT-ARC - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Chimeric Fusion Protein - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RNAi Oligonucleotides to Inhibit MAP Kinase for Liver Failure - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MicroRNA-221 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ImmuneSafe - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
albumin (human) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Liver Failure - Recent Pipeline Updates 57
Liver Failure - Dormant Projects 62
Liver Failure - Product Development Milestones 63
Featured News & Press Releases 63
Nov 27, 2013: NICE seeks more information on treatment for potentially serious liver condition 63
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 63
Apr 02, 2013: ALF-5755 phase II completion 64
Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury 64
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 65
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 66
May 06, 2011: ALF-5755 phase II extends to germany 67
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 67
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 67
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products under Development for Liver Failure, H2 2014 8
Number of Products under Development for Liver Failure - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Comparative Analysis by Unknown Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Liver Failure - Pipeline by Grifols, S.A., H2 2014 17
Liver Failure - Pipeline by Digna Biotech, S.L., H2 2014 18
Liver Failure - Pipeline by Ventria Bioscience, H2 2014 19
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 20
Liver Failure - Pipeline by Pharmicell Co., Ltd., H2 2014 21
Liver Failure - Pipeline by Alfact Innovation, H2 2014 22
Liver Failure - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Liver Failure Therapeutics - Recent Pipeline Updates, H2 2014 57
Liver Failure - Dormant Projects, H2 2014 62